Monday, June 13, 2016 7:40:09 PM
Item 7.01 Regulation FD Disclosure
While attending the Jefferies 2016 Healthcare Conference held in New York City from June 7-10, 2016, Dr. Douglas Mayers, Chief Medical Officer of Cocrystal Pharma, Inc. (the "Company") disclosed in private comments that the Company intends to pursue uplisting to the Nasdaq Stock Market in the coming year, in conjunction with which the Company would likely engage in capital-raising efforts. The Company is not presently engaged in an offering of the Company's securities and does not presently have any specific plans to raise capital. The Company cannot offer any assurances as to when, or if, the Company will apply to Nasdaq, and if the Company does apply to Nasdaq, it cannot offer any assurances as to whether the Company's securities will be accepted for listing.
The information in Item 7.01 of this report is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this report shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933.
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent COCP News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:15:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:00:46 PM
- Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/07/2024 08:30:24 PM
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:43 PM
- Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 02:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:40 PM
- Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 01:00:21 PM
- Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:01:00 PM
- Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:00:18 PM
- Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM